Detalhe da pesquisa
1.
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
Bioorg Med Chem
; 23(12): 2767-80, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25975640
2.
Efficient Route to Canagliflozin via Anhydroketopyranose.
Org Lett
; 24(19): 3450-3454, 2022 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35522756
3.
Corrigendum to "Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR" [Bioorg. Med. Chem. 23, 2015, 2767-2780].
Bioorg Med Chem
; 23(15): 5075, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32689707
4.
Characterization of Covalent-Reversible EGFR Inhibitors.
ACS Omega
; 2(4): 1563-1575, 2017 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29963651
5.
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
Cell Rep
; 20(12): 2833-2845, 2017 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28930680
6.
Identification and further development of potent TBK1 inhibitors.
ACS Chem Biol
; 10(1): 289-98, 2015 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25540906